Review of Pharmaceutical Solid Polymorphism: Preparation, Characterization and Influence on Performance of Drugs

Autor: Rumel Dey, Dona Roy Chowdhury
Jazyk: angličtina
Rok vydání: 2020
Předmět:
DOI: 10.5281/zenodo.3668628
Popis: When the crystalline structure of the same chemical compound (and atomic formula) exhibits two or more patterns of the repeated unit cells, these crystalline structures are called polymorphs and the phenomena is referred to as polymorphism. Active pharmaceutical ingredient (API) can have a variety of polymorph. These different Polymorphic forms of drug substance exhibits different physical and chemical properties, including melting point, chemical reactivity, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure and density. Polymorphism properties of API can have a direct effect on the ability to process and/or manufacture the API and the drug product. More importantly, polymorphisms of API directly affect drug product stability, dissolution and bioavailability. Hence, quality, safety and efficacy of the drug product can be directly affected by polymorphism. This review will discuss briefly the polymorphism preparation, characterization and their importance on drug substance and drug product.
{"references":["PH. Karpinski (2006), \"Polymorphism of active pharmaceutical ingredients\", Chem. Eng. Technol., Volume 29, Issue 2, pp. 233-237, Available at https://doi.org/10.1002/ceat.200500397","Garima Chawla and Arvind Kumar Bansal (2004), \"Challenges in polymorphism of pharmaceuticals\", CRIPS., Volume 5, Issue 1, pp. 12-15, Available at: https://www.researchgate.net/publication/286388735_Challenges_in_polymorphism_of_pharmaceuticals","Harry G. Brittain (2007), \"Polymorphism and solvatomorphism 2005\", J. of Pharm. Sci., Volume 96, Issue 4, pp. 705-728, Available at https://doi.org/10.1002/jps.20772","Center for Drug Evaluation and Research (2013), \"Guidance to industry: Regulatory classification of pharmaceutical co-crystals; Availability\", Food and Drug Administration, US Department of Health and Human Services, Available at: https://www.fda.gov/food/fda-food-code/food-code-2013","(2000), \"Q6A -Specifications: The procedures and acceptance criteria for new drug substances and new drug products: Chemical substances\", Int. Conf. on Harmo. of Tech. Require. for Regis. of Pharm. for Human Use., Volume 65, Issue 251, pp. 83041-83063, Available at https://www.govinfo.gov/content/pkg/FR-2000-12-29/pdf/FR-2000-12-29.pdf","Mino R. Caira, Eduard W. Pienaar and Antonie P. Lötter (2006), \"Polymorphism and Pseudopolymorphism of the Antibacterial Nitrofurantoin\", Molecular Crystals and Liquid Crystals, Volume 179, Issue 1, pp. 241-264, Available at https://doi.org/10.1080/10587259608042194","Giampiero Bettinetti, Milena Sorrenti, Laura Catenacci, Franca Ferrari and Silvia Rossi (2006), \"Polymorphism, pseudopolymorphism and amorphism of peracetylated α-, β- and γ-cyclodextrins\", J. of Pharm. and Biomed. Anal., Volume 41, Issue 4, pp.1205-1211, Available at https://doi.org/10.1016/j.jpba.2006.03.008.","J. Baue, J. Morley, S. Spanton, F.J.J. Leusen, R. Henry, S. Hollis, W. Heitmann A. Mannino, J. Quick and W. Dziki (2006), \"Identification, preparation and characterization of several polymorphs and solvates of terazosin hydrochloride\", J. of Pharm. Sci., Volume 95, Issue 4, pp. 917-928, Available at https://jpharmsci.org/article/S0022-3549(16)31981-5/fulltext","Peterson ML, Hickey MB, Zaworotko MJ and Almarsson O. (2006), \"Expanding the scope of crystal form evaluation in pharmaceutical science\", J of Pharm Sci, Volume 9, Issue 3, pp. 317-326, PMID: 17207415.","Kaisar Raza, Pramod Kumar, Shanti Ratan, Ruchi Malik and Shweta Arora (2014), \"Polymorphism: The Phenomenon Affecting the Performance of Drugs\", SOJ Pharma.and Pharm. Sci., Volume 1, Issue 2, 10, Available at http://dx.doi.org/10.15226/2374-6866/1/2/00111"]}
Databáze: OpenAIRE
Externí odkaz: